August 26, 2021
Takeda Pharmaceutical’s NEDD8-activating enzyme inhibitor pevonedistat has become the first drug to gain designation under the sakigake fast-track system since it earned the full legal backing under the amended Pharmaceuticals and Medical Devices (PMD) last year. The designation was announced...read more